JP2019535822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535822A5 JP2019535822A5 JP2019547064A JP2019547064A JP2019535822A5 JP 2019535822 A5 JP2019535822 A5 JP 2019535822A5 JP 2019547064 A JP2019547064 A JP 2019547064A JP 2019547064 A JP2019547064 A JP 2019547064A JP 2019535822 A5 JP2019535822 A5 JP 2019535822A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- liver
- reducing
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 210000004185 liver Anatomy 0.000 claims 5
- 102000023984 PPAR alpha Human genes 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims 2
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 102000004311 liver X receptors Human genes 0.000 claims 2
- 108090000865 liver X receptors Proteins 0.000 claims 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 2
- 229960003073 pirfenidone Drugs 0.000 claims 2
- 239000007939 sustained release tablet Substances 0.000 claims 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 claims 1
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- -1 IL-1β Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 101710091439 Major capsid protein 1 Proteins 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 claims 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 claims 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022152261A JP2022173344A (ja) | 2016-11-11 | 2022-09-26 | ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXMX/A/2016/014775 | 2016-11-11 | ||
| MX2016014775A MX364040B (es) | 2016-11-11 | 2016-11-11 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
| PCT/MX2017/000129 WO2018088886A1 (es) | 2016-11-11 | 2017-11-09 | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152261A Division JP2022173344A (ja) | 2016-11-11 | 2022-09-26 | ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535822A JP2019535822A (ja) | 2019-12-12 |
| JP2019535822A5 true JP2019535822A5 (enExample) | 2020-12-17 |
Family
ID=61193005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547064A Pending JP2019535822A (ja) | 2016-11-11 | 2017-11-09 | ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 |
| JP2022152261A Pending JP2022173344A (ja) | 2016-11-11 | 2022-09-26 | ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152261A Pending JP2022173344A (ja) | 2016-11-11 | 2022-09-26 | ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20190262325A1 (enExample) |
| EP (1) | EP3539537A1 (enExample) |
| JP (2) | JP2019535822A (enExample) |
| KR (2) | KR20190084056A (enExample) |
| CN (2) | CN110248646A (enExample) |
| AR (1) | AR110057A1 (enExample) |
| AU (2) | AU2017358367B2 (enExample) |
| CA (1) | CA3043300A1 (enExample) |
| CL (1) | CL2019001280A1 (enExample) |
| CO (1) | CO2019004799A2 (enExample) |
| EC (1) | ECSP19031851A (enExample) |
| IL (1) | IL266519A (enExample) |
| JO (1) | JOP20190102A1 (enExample) |
| MA (1) | MA45754A1 (enExample) |
| MX (1) | MX364040B (enExample) |
| PE (1) | PE20191149A1 (enExample) |
| PH (1) | PH12019501047A1 (enExample) |
| RU (1) | RU2019116422A (enExample) |
| UY (1) | UY37478A (enExample) |
| WO (1) | WO2018088886A1 (enExample) |
| ZA (1) | ZA201903012B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| EP3716975A4 (en) * | 2017-11-28 | 2022-01-12 | Eiger Biopharmaceuticals, Inc. | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
| WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
| EP4232063A4 (en) * | 2020-10-23 | 2025-01-01 | HAN, Hq | BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES |
| CN117007806A (zh) * | 2023-09-21 | 2023-11-07 | 中国人民解放军军事科学院军事医学研究院 | 靶向肝巨噬细胞内lxr用于控制慢乙肝进展 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60234812D1 (de) * | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| CN100542532C (zh) * | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途 |
| WO2010048716A1 (en) * | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CN102488660A (zh) * | 2011-12-15 | 2012-06-13 | 西安天一秦昆制药有限责任公司 | 一种含吡非尼酮的缓释微丸 |
| CN103550242B (zh) * | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
-
2016
- 2016-11-11 MX MX2016014775A patent/MX364040B/es active IP Right Grant
-
2017
- 2017-06-16 JO JOP/2019/0102A patent/JOP20190102A1/ar unknown
- 2017-11-09 CA CA3043300A patent/CA3043300A1/en active Pending
- 2017-11-09 UY UY0001037478A patent/UY37478A/es not_active Application Discontinuation
- 2017-11-09 JP JP2019547064A patent/JP2019535822A/ja active Pending
- 2017-11-09 AU AU2017358367A patent/AU2017358367B2/en active Active
- 2017-11-09 KR KR1020197014274A patent/KR20190084056A/ko not_active Ceased
- 2017-11-09 KR KR1020247015017A patent/KR20240065330A/ko not_active Ceased
- 2017-11-09 US US16/348,189 patent/US20190262325A1/en not_active Abandoned
- 2017-11-09 RU RU2019116422A patent/RU2019116422A/ru unknown
- 2017-11-09 WO PCT/MX2017/000129 patent/WO2018088886A1/es not_active Ceased
- 2017-11-09 CN CN201780076430.3A patent/CN110248646A/zh active Pending
- 2017-11-09 MA MA45754A patent/MA45754A1/fr unknown
- 2017-11-09 CN CN202211265065.XA patent/CN115969802A/zh active Pending
- 2017-11-09 PE PE2019000946A patent/PE20191149A1/es unknown
- 2017-11-09 EP EP17840578.3A patent/EP3539537A1/en active Pending
- 2017-11-10 AR ARP170103142A patent/AR110057A1/es unknown
-
2019
- 2019-05-08 EC ECSENADI201931851A patent/ECSP19031851A/es unknown
- 2019-05-08 IL IL266519A patent/IL266519A/en unknown
- 2019-05-09 CL CL2019001280A patent/CL2019001280A1/es unknown
- 2019-05-10 CO CONC2019/0004799A patent/CO2019004799A2/es unknown
- 2019-05-10 PH PH12019501047A patent/PH12019501047A1/en unknown
- 2019-05-14 ZA ZA2019/03012A patent/ZA201903012B/en unknown
-
2022
- 2022-09-26 JP JP2022152261A patent/JP2022173344A/ja active Pending
- 2022-11-02 US US18/051,937 patent/US20230181550A1/en not_active Abandoned
-
2024
- 2024-02-07 AU AU2024200737A patent/AU2024200737A1/en active Pending
- 2024-12-02 US US18/965,593 patent/US20250325530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535822A5 (enExample) | ||
| JP2017178948A5 (enExample) | ||
| JP2018184443A5 (enExample) | ||
| WO2017141104A3 (en) | Method for inducing a sustained immune response | |
| HRP20230170T1 (hr) | Derivati kolana za uporabu u liječenju i/ili prevenciji bolesti povezanih s fxr i tgr5/gpbar1 | |
| JP2018504445A5 (enExample) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| MX2017001372A (es) | Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas. | |
| WO2005087238A3 (en) | Method for stimulating the immune, inflammatory or neuroprotective response | |
| NZ741082A (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
| HK1232147A1 (zh) | 用於治疗纤维化的赛尼克韦罗 | |
| RU2019116422A (ru) | Фармацевтическое применение композиции пролонгированного действия, содержащей пирфенидон, для лечения и обращения течения стеатогепатита человека (nafld/nash) | |
| RU2016145066A (ru) | Композиция для предотвращения или лечения жировых болезней печени | |
| JP2015535270A5 (enExample) | ||
| EP3833373A4 (en) | TRIPEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISEASES | |
| JP2017512194A5 (enExample) | ||
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| MX2020011474A (es) | Nuevo tratamiento de enfermedades pulmonares intersticiales. | |
| CN110546150A (zh) | 含吡唑基的三并环类衍生物、其制备方法和应用 | |
| WO2016040462A3 (en) | Formulations and methods for treatment of metabolic syndrome | |
| EP4221704A4 (en) | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES | |
| JP2017061488A5 (enExample) | ||
| ZA201905309B (en) | Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals |